USMF logo

Institutional Repository in Medical Sciences
of Nicolae Testemitanu State University of Medicine and Pharmacy
of the Republic of Moldova
(IRMS – Nicolae Testemitanu SUMPh)

Biblioteca Stiintifica Medicala
DSpace

University homepage  |  Library homepage

 
 
Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12710/18631
Title: Combined otologic drugs on pharmaceutical market of Moldova
Authors: Luca, Angela
Staver, Olga
Keywords: fixed-dose combinations;combined drugs;anti-adhesive substances;keloids
Issue Date: 2014
Publisher: Ministry of Health of the Republic of Moldova, State Medical and Pharmaceutical University Nicolae Testemitanu, Medical Students and Residents Association
Citation: LUCA, Angela, STAVER, Olga. Combined otologic drugs on pharmaceutical market of Moldova. In: MedEspera: the 5th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2014, pp. 239-240.
Abstract: Introduction: About one-tenth of medicinal products present on the pharmaceutical market are fixed-dose combinations. Fixed-dose combination products are becoming a popular treatment option because of increased patient’s compliance and convenience, improved clinical effectiveness, reduced cost for the patient and reduced side effects. Due to this range of advantages, combined drugs can be used in otorhinolaryngology practice, especially in the pharmacotherapy of ear diseases, because of the severe consequences otitis media produces (such as deafness due to keloid scars of the tympanic membrane). Materials and methods: For research, State Nomenclature of medicines from Republic of Moldova was used (26.03.2014); patient information leaflets; quality standards of analytical documents and therapeutic protocols in otorhinolaryngology (section "ear diseases"). Results: There are 642 combined drugs including: 531 combined drugs, 75 phytotherapeutic combined drugs and 36 biological combined drugs registered in State Nomenclature of drugs from Republic of Moldova. From these, approved drugs in otorhinolaryngology are 87 combined drugs, 20 phytotherapeutic combined drugs and 1 biological combined drug, which represents 13,55%, 3,11% and 0,15% from the total number of registered fixed-dose combination products, respectively, 16,38%, 26,67% and 2,77% from the number of registered specific combined products. There are 5 registered otological drugs which represents 0,78% from the total number of registered fixed-dose combination products and respectively, 0,94% from the number of registered specific combined products. From these: 40% represents anti-infectives, 20% represents analgesics and anesthetics and 40% represents corticosteroids and anti-infectives in combination. So, there is no specific anti-adhesive drug combination for the treatment of eardrum keloids. Conclusions: In conclusion it is important to develop a new anti-adhesive composition for the treatment of keloids of the tympanic membrane, containing raw vegetable materials.
metadata.dc.relation.ispartof: MedEspera: The 5th International Medical Congress for Students and Young Doctors, May 14-17, 2014, Chisinau, Republic of Moldova
URI: http://repository.usmf.md/handle/20.500.12710/18631
Appears in Collections:MedEspera 2014

Files in This Item:
File Description SizeFormat 
COMBINED_OTOLOGIC_DRUGS_ON_PHARMACEUTICAL_MARKET_OF_MOLDOVA.pdf119.6 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

 

Valid XHTML 1.0! DSpace Software Copyright © 2002-2013  Duraspace - Feedback